Intrathecal baclofen for the treatment of spinal myoclonus: a case series

Chiodo, Anthony E.; Saval, April

doi:10.1179/2045772311y.0000000006

Cited by 18 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another compound used in treating SCI is baclofen, a Gamma-aminobutyric acid type B (GABAb) receptor agonist that is able to relieve spasticity related to motor disorders ( Chiodo and Saval, 2012 ;Barry et al, 2013 ). The beneficial effects of baclofen on motor recovery result from regulation of the synaptic transmission at spinal and supraspinal sites ( Curtis et al, 1997 ).…”

Section: Molecular and Cellular Approaches For Scimentioning

confidence: 99%

Spinal cord injury: overview of experimental approaches used to restore locomotor activity

Fakhoury

2015

Reviews in the Neurosciences

View full text Add to dashboard Cite

AbstractSpinal cord injury affects more than 2.5 million people worldwide and can lead to paraplegia and quadriplegia. Anatomical discontinuity in the spinal cord results in disruption of the impulse conduction that causes temporary or permanent changes in the cord’s normal functions. Although axonal regeneration is limited, damage to the spinal cord is often accompanied by spontaneous plasticity and axon regeneration that help improve sensory and motor skills. The recovery process depends mainly on synaptic plasticity in the preexisting circuits and on the formation of new pathways through collateral sprouting into neighboring denervated territories. However, spontaneous recovery after spinal cord injury can go on for several years, and the degree of recovery is very limited. Therefore, the development of new approaches that could accelerate the gain of motor function is of high priority to patients with damaged spinal cord. Although there are no fully restorative treatments for spinal injury, various rehabilitative approaches have been tested in animal models and have reached clinical trials. In this paper, a closer look will be given at the potential therapies that could facilitate axonal regeneration and improve locomotor recovery after injury to the spinal cord. This article highlights the application of several interventions including locomotor training, molecular and cellular treatments, and spinal cord stimulation in the field of rehabilitation research. Studies investigating therapeutic approaches in both animal models and individuals with injured spinal cords will be presented.

show abstract

Section: Molecular and Cellular Approaches For Scimentioning

confidence: 99%

Spinal cord injury: overview of experimental approaches used to restore locomotor activity

Fakhoury

2015

Reviews in the Neurosciences

View full text Add to dashboard Cite

show abstract

“…Several cases have been identified in which ITB therapy was attempted for myoclonus induced by mechanisms other than HBI. Chiodo and Saval [ 10 ] demonstrated cases of secondary myoclonus of spinal origin utilizing ITB in the treatment. Zhang et al [ 11 ] reported on controlling painful muscles in a 38-year-old woman presenting with stiff-person syndrome.…”

Section: Discussionmentioning

confidence: 99%

“…ITB for myoclonus from spinal cord injury decreases inter-neuron inhibition leading to myoclonus, which might be a similar mechanism to that from HBI. It would be merely different in terms of administration doses, duration, and treatment response rate, associated with several factors such as drug concentrations in cerebrospinal fluid [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Successful Control of Intractable Myoclonus in a Patient With Hypoxic Brain Injury After Intrathecal Baclofen Therapy: A Case Report

Lee

Kim

2022

Brain Neurorehabil

View full text Add to dashboard Cite

Myoclonus is an abrupt arrhythmic condition with shock-like movements that can be triggered by sensory stimuli, affecting the trunk or limbs during voluntary movement. Since motor symptoms are often not easily treatable, various pharmacological treatment options have been suggested. We report a case of using intrathecal baclofen (ITB) therapy in a patient with hypoxic brain injury (HBI), leading to the alleviation of myoclonus. A 29-year-old woman repeatedly presented with generalized myoclonus and multiple joint contractures at both upper and lower limbs after resuscitation. She cried during intractable myoclonus events, making it difficult for her to maintain a good sleep pattern. Due to the persistent status of multiple joint contractures and intractable myoclonus, we offered an ITB trial to control her symptoms. After ITB, her total scores on the Unified Myoclonus Rating Scale progressively improved as the doses of baclofen increased. Therefore, ITB therapy should be considered as a substantial option in the management of intractable myoclonus in patients with HBI to prevent various complications and improve the quality of life.

show abstract

“…Intrathecal baclofen (ITB) has beneficial effects in pediatric patients with progressive neurological disease, as shown in the reports by Bonouvrié et al [19]. In 2012, the successful use of ITB has been reported in patients with dystonia [20,21], myoclonus [22], dysautonomia, and hypertonia following severe traumatic brain injury [23]. In patients with complex regional pain syndromes with dystonia, van der Plas et al [24] demonstrated a significant improvement in global intense pain, sharp pain, dull pain, and deep pain during the first 6 months.…”

Section: Baclofenmentioning

confidence: 99%